MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Gastroenterology_Gastrointestinal (to include Liver, Pancreas & metabolic dysfunction-associated steatotic liver disease (MASLD), Gout, MASH (Metabolic dysfunction-associated steatohepatitis), formerly, NASH (Non-Alcoholic SteatoHepatitis)Non-Alcoholic SteatoHepatitis (NASH)
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT)*
Organization & Developments: Phantom Pharmaceuticals
Parents
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT)*
Children
*Phathom Pharmaceuticals is a late clinical-stage biopharmaceutical company committed to transforming the treatment landscape and improving the lives of patients suffering from acid-related gastrointestinal (GI) disorders.
2021: Phathom Pharmaceuticals: Bringing Vonoprazan To U.S. And Europe Ought To Be Straightforward And Lucrative
2022: Phathom Pharma: Approved Drugs, Upcoming PDUFA, Smallish Addressable Market_ seekingalpha.com
2023: Phathom Pharma Is A Buy Before July PDUFA_ seekingalpha.com
2024: Phathom Pharmaceuticals aims to 'kick some acid' with first Voquezna campaign
2024: Phathom Pharmaceuticals: The Large Drop Is, Well, Unfathomable_seekingalpha.com
2024: Phathom Scores Non-Erosive GERD Approval for Heartburn Drug
2024: Phathom: Undervalued Biotech With Possible GERD Treatment Label Expansion
2024: Phathom's Voquezna: A Breakthrough Drug Facing Marketing Challenges
2025: Phathom Pharmaceuticals Announces Positive FDA Decision to Recognize 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets through May 3, 2032
2025: Phathom: Share Price Surge On Patent News May Not Stop The Rot For Long
Jumps
Finance & Acquisitions: Phantom Pharmaceuticals
Key People: Phantom Pharmaceuticals